The regulatory approval of EPKINLY Combo by the FDA has spearheaded a fresh perspective on investing in AbbVie (ABBV). In addition, market experts recommend a long position on the company's stocks. AbbVie alongside Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories witnessed a favorable stock market trend. Furthermore, AbbVie’s FDA approval for its EPKINLY FL combo reduced its risk by 79% in relapsed FL. Nonetheless, the company has seen some fluctuations, experiencing a decrease in shares, despite analysts suggesting a strong valuation. On the upswing, AbbVie has raised its guidance after an earnings beat and established new patent protection. The dividend has been increased to $1.73, making it an appealing option to Baron Health Care Fund, which added AbbVie to its portfolio. There's been discussion about a possible dividend hike buffing up its investment appeal and Q3 earnings and revenue comfortably beat estimates. Piper Sandler has upped the price target to $289, maintaining an overweight rating. While an impressive 28% year-to-date rise in share price makes AbbVie an attractive prospect, concerns of margin compression and a $14.5 billion one-off loss have led to some caution among investors.
Abbvie ABBV News Analytics from Thu, 10 Jul 2025 07:00:00 GMT to Sat, 22 Nov 2025 03:45:00 GMT - Rating 7 - Innovation 3 - Information 8 - Rumor 4
